| |
| |
|
| Insider
Information: |
Francois Cedric |
| Relationship: |
Chief Executive Office... |
| City: |
Crestwood |
| State: |
KY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
313,662 |
|
|
Indirect Shares
|
1,721,568 |
|
|
| Direct
Value |
$13,769,762 |
|
|
|
Indirect Value
|
$75,576,835 |
|
|
| Total
Shares |
2,035,230 |
|
|
| Total
Value |
$89,346,597 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -116.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Executive Office... |
2024-03-01 |
313,662 |
2024-03-01 |
1,721,568 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-03-01 |
4 |
AS |
$62.21 |
$16,028,706 |
D/D |
(250,000) |
313,662 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-03-01 |
4 |
OE |
$3.76 |
$1,050,000 |
D/D |
250,000 |
563,662 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-02-12 |
4 |
S |
$67.77 |
$268,492 |
D/D |
(3,962) |
313,662 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-01-29 |
4 |
S |
$64.14 |
$182,345 |
D/D |
(2,843) |
317,624 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-01-22 |
4 |
S |
$65.00 |
$872,961 |
D/D |
(13,431) |
320,467 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-01-16 |
4 |
S |
$66.81 |
$524,514 |
D/D |
(7,851) |
333,898 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
72,094 |
341,749 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-11-21 |
4 |
S |
$48.80 |
$244,000 |
D/D |
(5,000) |
269,655 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-09-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
150,000 |
274,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-09-19 |
4 |
GA |
$0.00 |
$0 |
I/I |
150,000 |
804,211 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
20,000 |
654,211 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
274,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-17 |
4 |
OE |
$2.67 |
$53,400 |
D/D |
20,000 |
294,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-16 |
4 |
OE |
$2.67 |
$80,100 |
D/D |
30,000 |
304,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-05-16 |
4 |
AS |
$83.17 |
$2,569,900 |
D/D |
(30,000) |
274,655 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
382,946 |
382,946 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
382,946 |
274,655 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-19 |
4 |
OE |
$2.67 |
$53,400 |
D/D |
20,000 |
657,601 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-18 |
4 |
AS |
$82.02 |
$2,460,720 |
D/D |
(30,000) |
637,601 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-18 |
4 |
OE |
$2.67 |
$80,100 |
D/D |
30,000 |
667,601 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-05 |
4 |
GA |
$0.00 |
$0 |
I/I |
26,990 |
634,211 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
26,990 |
637,601 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
380,000 |
607,221 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
380,000 |
664,591 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-04-03 |
4 |
GA |
$0.00 |
$0 |
I/I |
227,221 |
227,221 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
